This inventor holds 2 USPTO granted patents and 4 published patent applications. Top assignee: Magenta Therapeutics, Inc.. Active years: 2021-2023.
Company Filing History:
Years Active: 2021-2023
Title: Innovations by Jonathan Philip Belk
Introduction
Jonathan Philip Belk is a notable inventor based in Grantham, NH (US). He has made significant contributions to the field of biomedical research, particularly in the development of therapies targeting hematopoietic diseases and cancers. With a total of 2 patents, his work has the potential to impact various medical treatments.
Latest Patents
Belk's latest patents include innovations related to Anti-CD117 antibodies and conjugates. These inventions provide compositions and methods useful for the depletion of CD117+ cells, which are crucial in treating various hematopoietic diseases, metabolic disorders, cancers, and autoimmune diseases. The described antibodies and conjugates can effectively deplete CD117+ cancer cells or autoimmune cells in patients. Furthermore, these compositions can prepare patients for hematopoietic stem cell transplant therapy, improving the engraftment of transplants by selectively depleting endogenous hematopoietic stem cells prior to the procedure.
Career Highlights
Belk is currently associated with Magenta Therapeutics, Inc., where he continues to advance his research and innovations. His work is instrumental in developing new therapeutic strategies that can significantly improve patient outcomes in hematological conditions.
Collaborations
Some of his notable coworkers include Anthony Boitano and Sean McDonough, who collaborate with him on various projects within the company.
Conclusion
Jonathan Philip Belk's contributions to the field of biomedical research through his patents and work at Magenta Therapeutics, Inc. highlight his commitment to advancing medical science and improving patient care.